
Lirafugratinib + LITESPARK011
OncoPharm
00:00
Progression-Free Survival Favors Combination Therapy
John Bazar reports significantly improved progression-free survival and higher response rates with lenvatinib plus belzutifan compared with cabozantinib.
Play episode from 09:59
Transcript


